Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 75/100

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Key Takeaway: Invivyd, Inc. has announced its participation in the Guggenheim Securities Healthcare Innovation Conference scheduled for November 11-13, 2024. Management will take part in a fireside chat and hold one-on-one meetings with investors. The company is recognized for its efforts in combating serious viral infectious diseases through its proprietary INVYMAB platform, which has already garnered emergency use authorization for its first monoclonal antibody from the U.S. FDA.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is actively engaging with investors at a significant conference.
  • The company has a proactive approach to addressing viral diseases with innovative solutions.
  • Invivyd has received emergency use authorization for its mAb product, indicating progress in its pipeline.

Full Press Release Details

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that management will participate in a fireside chat and 1x1 investor meetings at the Guggenheim Securities Healthcare Innovation Conference taking place November 11-13, 2024.
Fireside Chat: Wednesday, November 13, 2024 at 2:30 PM ET
Location: Boston, MA
The live webcast link will be available in the investor section of the company's website at https://investors.invivyd.com and will be archived for approximately 30 days following the event.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Frequently Asked Questions

When is the Guggenheim Healthcare Innovation Conference?

The conference will be held from November 11 to 13, 2024.

What is Invivyd’s primary focus?

Invivyd focuses on providing protection against serious viral infectious diseases.

What platform does Invivyd use for antibody development?

Invivyd employs the INVYMAB™ platform for developing monoclonal antibodies.

When will the fireside chat take place?

The fireside chat is scheduled for November 13, 2024, at 2:30 PM ET.

Where can I find the webcast of the fireside chat?

The webcast can be accessed on Invivyd's investor website section.

Last updated: Nov 6, 2024